Old Cialis News
Cialis turns profit, builds market share [Read Article] (October 21, 2005)
LILLY ICOS Study Shows Cialis Also Improves Enlarged Prostate Symptoms [Read Article]
Cialis Western Open Final Round Betting ODDS [Read Articles] (07/03/2005)
House bans Medicare coverage for Viagra, Cialis [Read Articles] (06/24/2005)
Cialis (tadalafil) Overtakes Viagra to Become Number One Selling Erectile
Dysfunction Treatment in France [Read Articles] (06/15/2005)
PDE-5 inhibitor rises to erectile dysfunction challenge [Read Articles] (06/08/2005)
Cialis becomes the 'Premium Erectile Dysfunction Drug' in World Market [Read Article]
Parker & Waichman, LLP Contacted by Viagra, Cialis & Levitra Users Claiming Vision Problems, Blindness & Other Side Effects; [Read Article] (June 3, 2005)
The FDA has approved updated labeling for the erectile dysfunction drugs Cialis, Levitra, and Viagra [Read Article] (Monday, July 11, 2005)
FDA Investigates Reports Of Blindness Among Some Viagra And Cialis Users [Read Articles]
Viagra, Cialis battle spills over to India [Read Articles] (05/20/2005)
Trademark of Lilly ICOS LLC - Cialis has become the SPAM [Read Articles] (05/19/2005)
Cops seized 29 000 Viagra pills and 14 436 Cialis [Read Articles] (02/14/2005)
Cialis buying time in the Super Bowl [Read Articles] (WTHR, IN - Feb 4, 2005)
ICOS says Cialis marketing should pay off in '05 sales [Read Article] (Seattle Times, 02/04/2005)
Fake viagra capsules from Far East flooding country [Read Article] (DailyNews, 02/17/2005)
Viagra: It's Also Good For Your Heart [Read Article] (Forbes, 01/24/05)
Aggressive goals set by ICOS are hitting the mark [Read Article] (The Seattle Times, 11/05/04)
Is it best to Buy Cialis? Or do we go for Viagra or Levitra? [Read Article] (PR Web.com, 6/24/04)
More Cialis News, Cialis Articles and Press Releases
|
|
Sales of Viagra, Cialis Levitra slower than expected
Although the producers of drugs treating male erectile dysfunction – Cialis, Viagra, Levitra, invested lots of money in advertising, the sales were not as good as industry leaders had estimated. Sales reported for these drugs in 2004 reached $2.7 billion, but the companies that made them had predicted at least $1 billion more.
|
|
